Although current therapy for acute ischemic stroke remains limited to intravenous recombinant tissue plasminogen activator (tPA) administered within 3 hours of symptom onset, other treatment options are on the horizon.
Here we discuss recent and ongoing research that may:
- Broaden the criteria for thrombolysis with tPA so that more patients with stroke can benefit from treatment.
- Extend the 3-hour window in select patients.
- Expand the armamentarium to include more effective thrombolytic agents, alternative means of delivery of thrombolytics, mechanical approaches to clot lysis, neuroprotective therapies, and combination thrombolytic/neuroprotective therapies.
CURRENT THERAPY: tPA AND THE 3-HOUR WINDOW
In 1996, the FDA approved the use of intravenous tPA for acute ischemic stroke. This was a landmark in the history of stroke treatment; before that time, thrombolytic therapy was not recommended for patients with stroke.
The approval of tPA was based primarily on the results of the National Institute of Neurological Disorders and Stroke (NINDS) tPA Stroke Study, in which 624 patients with ischemic stroke received placebo or tPA within 3 hours of symptom onset. Approximately 50% of study participants were treated within 90 minutes of stroke onset.1 Initiation of tPA therapy within 90 minutes was associated with an odds ratio of 2.83 for a favorable outcome (95% confidence interval [CI], 1.77 to 4.53); if therapy was started between 90 and 180 minutes after symptom onset, the odds ratio was 1.53 (95% CI, 1.11 to 2.11).2
The patients who had received tPA had a 30% greater probability of recovering with little or no deficit after 3 months, as assessed by multiple outcome measures. The benefits associated with tPA treatment were maintained at 1 year.3
Patients who were most likely to have an excellent outcome were those younger than 75 years and those who had a mild to moderate stroke (as indicated by a score of less than 20 on the National Institutes of Health Stroke Scale [NIHSS], which is available at www.strokecenter.org/trials/scales/ nihss.pdf.). Nonetheless, tPA treatment improved the likelihood of a favorable outcome in patients with severe stroke (NIHSS score greater than 20) and in older patients.1
The major risk associated with tPA treatment was symptomatic intracerebral hemorrhage (ICH), which occurred in 6.4% of patients who received tPA but in only 0.6% of those in the placebo group. However, there was no significant difference in mortality at 3 months (17% of patients who received tPA and 20% of those who received placebo) or at 1 year (24% and 28%, respectively).1,3
Since the NINDS study results were published, several other groups have reported similar efficacy and safety data for tPA treatment. Despite this strong evidence, only 2% to 4% of all stroke patients currently receive tPA.4 The major impediment to use of tPA is the late arrival of many stroke patients at the emergency department for evaluation and treatment. Thus, it is important to teach patients about the signs and symptoms of stroke so they know when to seek medical care.
1. Marler JR, for the NINDS Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;24:1581-1587.
2. Fisher M, Brott TG. Emerging therapies for acute ischemic stroke: new therapies on trial. Stroke. 2003;34:362-364.
3. Kwiatkowski T, Libman R, Frankel M, et al, and the NINDS rt-PA Stroke Study Group. The NINDS rt-PA Stroke Study: sustained benefit at one year [abstract]. Stroke. 1998;29:288.
4. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for an ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med. 1999;33:9-14.
5. Hacke W, Brott T, Caplan L, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology. 1999;53(suppl 4):S3-S14.
6. Wardlaw J, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2000;(2):CD000213.
7. Adams H, Brott T, Crowell R, et al. Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1994:25:1901-1914.
8. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997; 28:957-960.
9. Patel SC, Levine SR, Tilley BC, et al, for the NINDS Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001;286:2830-2838.
10. von Kummer R, Meyding-Lamade U, Forsting M, et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. Am J Neuroradiol. 1994;15: 9-15.
11. von Kummer R, Allen KL, Holle R, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology. 1997;205:327-333.
12. Hacke W, Kaste M, Olsen TS, et al, for the European Stroke Initiative Writing Committee. European Stroke Initiative (EUSI) recommendations for stroke management Eur J Neurol. 2000;7: 607-623.
13. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow-up study. BMJ. 1997;314:1303-1306.
14.Bruno A, Biller J, Adams HP, et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) investigators. Neurology. 1999;52: 280-284.
15.Demchuk AM, Tanne D, Hill MD, et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57:474-480.
16.Bruno A, Levine SR, Frankel MR, et al. Admis-sion glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002;59:669-674.
17. Schellinger PD, Fiebach JD, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke. 2003;34: 575-583.
18. Rother J, Schellinger PD, Gass A, et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke Stroke. 2002;33:2438-2445.
19. Furlan A, Higashida RT, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: Prolysis in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
20.Schellinger PD, Fiebach JB, Mohr A, et al. Thrombolytic therapy for ischemic stroke-a review, part II: intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging. Crit Care Med. 2001;29:1819-1825.
21. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30:2598-2605.
22. Qureshi AI, Ali Z, Suri MF, et al. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neuro- surgery. 2001;49:41-50.
23. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA. 2000;283:2395-2403.
24. Adams HP, Bogousslavski J, Cook R, et al. The safety and efficacy of abciximab in acute ischemic stroke[abstract]. Ann Neurol. 2002;52:S64.
25. Qureshi AI, Suri MF, Khan J, et al. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience. Neurosurgery. 2000;46:1316-1325.
26. McDonald CT, O'Donnell J, Bemporad J, et al. The clinical utility of intravenous integrilin combined with intra-arterial tissue plasminogen activator in acute ischemic stroke. The MGH experience [abstract]. Stroke. 2002;33:S359.
27. Chopko BW, Kerber C, Wong W, Georgy B. Transcatheter snare removal of acute middle cerebral artery thrombembolism: technical case report. Neurosurgery. 2000;40:1529-1531.
28. Clark WM, Lutsep HL, Barnwell SL, et al. Multicenter feasibility study of an ultrasound drug infusion microcatheter for treatment of acute ischemic stroke [abstract]. Stroke. 2002;33: S359.
29. Hossmann K-A. Viability thresholds and the penumbra of focal ischemia. Ann Neurol. 1994;36: 557-565.
30.Ye ZR, Liu KF, Garcia JH. Mechanisms of neuronal cell death after ischemic brain injury. In: Fisher M, Bogousslausky J, eds. Current Review of Cerebrovascular Disease. 4th ed. Philadelphia: Current Medicine; 2001:15-24.
31.Fisher M, for the Stroke Therapy Academic Industry Roundtable. Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke. 2003;34:1539-1546.
32. Saver JL, Kidwell CS, Hamilton S, et al. The Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Phase 3 Trial. Ongoing Clinical Trials Session, 28th International Stroke Conference; February 13 - 15, 2003; Phoenix. Abstract CTP17.
33. Fisher M, Ratan R. New perspectives on developing acute stroke therapy. Ann Neurol. 2003;53:10-20.